Biotech Essentials

Startups

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 02.06.2021.

#biotech
#FDA
#KRAS
#research
#COVID19
#GoodDayBIO
#IPO

Startups

@BentheFidler shared
On Jun 1, 2021
RT @LifeSciVC: Biotech’s Relevancy Challenge In An Expanding Universe The pace of new names to invest in (supply of opportunities from IPOs) has increased faster than the number of potential “big” holders (demand for new core positions in public fund portfolios) https://t.co/hoxofSGa9E
Open
Biotech’s Relevancy Challenge In An Expanding Universe

Biotech’s Relevancy Challenge In An Expanding Universe

The universe of public biotech companies has been growing for a decade, and increasingly so in the past few years as the IPO market has flourished. Hundreds of young aspiring biotechs have ...

@big4bio shared
On Jun 1, 2021
Eight years ago, @Amgen ($AMGN) made an X-ray image of KRAS protein's molecular structure. Now they have developed a viable drug, Lumakras, as a therapy for non-small cell lung cancer patients with #KRAS mutations. #biotech #research #FDA Read more here: https://t.co/jgZXspTeqU
Open
How a protein 'Polaroid' led Amgen to finally crack the 'Achilles heel tumor' with Lumakras in 8 years

How a protein 'Polaroid' led Amgen to finally crack the 'Achilles heel tumor' with Lumakras in 8 years

Two of Amgen’s R&D and clinical development experts gave Fierce Biotech a snapshot into the light-speed development process that brought Lumakras, formerly known as sotorasib, to the cusp ...

@IAmBiotech shared
On May 27, 2021
#GoodDayBIO: News on two bills that would streamline reporting requirements for Emerging Growth Companies and provide biofuel tax credits, as well as what @Nick_Offerman #COVID19 vaccines. https://t.co/w9EefonVy1
Open
Good Day BIO: Startups, SAF tax credits, and Ron Swanson

Good Day BIO: Startups, SAF tax credits, and Ron Swanson

If you thought D.C. would slow down ahead of Memorial Day, think again. Today, news on two bills that would streamline reporting requirements for Emerging Growth Companies and provide ...

@ScottKirsner shared
On May 28, 2021
Despite the ending of COVID restrictions, there’s no rush to schedule networking events and conventions https://t.co/ehLYd8Dcl0 via @BostonGlobe
Open
Despite the ending of COVID restrictions, there’s no rush to schedule networking events and conventions

Despite the ending of COVID restrictions, there’s no rush to schedule networking events and conventions

If you’re holding a cold beer at 5 p.m. and learning about social media marketing or how to raise money for your startup, chances are you’re still staring into a screen.

@FierceBiotech shared
On May 27, 2021
The deal, anticipated to close in the third quarter, includes up to $175 million in a trust and a fully committed $60 million private investment in public equity from founding series A investors https://t.co/8DNDXh9euV
Open
EFFECTOR Therapeutics bugs out of an IPO, taking the SPAC path with Locust Walk

EFFECTOR Therapeutics bugs out of an IPO, taking the SPAC path with Locust Walk

EFFECTOR Therapeutics thinks it can be effective in clinical trial advancement following SPAC merger with Locust Walk

@FierceBiotech shared
On Jun 2, 2021
Genmab is contributing its own antibodies and bispecific antibody engineering technologies to the collaboration, positioning the partners to develop a twist on the ISAC concept https://t.co/IP63t1GATi
Open
Genmab joins with Bolt to develop bispecific immune stimulators

Genmab joins with Bolt to develop bispecific immune stimulators

Genmab and Bolt Biotherapeutics have teamed up to develop bispecific immune-stimulating antibody conjugates. The collaboration brings together Genmab’s bispecific capabilities with Bolt’s ...

@BentheFidler shared
On May 28, 2021
Centessa raises $330M in third largest #biotech #IPO this year https://t.co/zQ08vZVTwn by @NedPagliarulo $CNTA
Open
Centessa raises $330M in third largest biotech IPO this year

Centessa raises $330M in third largest biotech IPO this year

The public offering follows just three months after Centessa, created from the merger of 10 Medicxi-backed drug startups, launched with $250 million in venture funding.

@GENbio shared
On Jun 2, 2021
RT @AlexWestchester: 2June: What clinical data drove @Amgen to co-develop Kyowa Kirin's atopic dermatitis candidate KHK4083 in an up-to-$1.2B partnership? My latest for @GENbio: https://t.co/HoI8JnaAw1
Open
Amgen to Co-Develop Kyowa Kirin’s Atopic Dermatitis Candidate in Up-to-$1.2B Partnership

Amgen to Co-Develop Kyowa Kirin’s Atopic Dermatitis Candidate in Up-to-$1.2B Partnership

Amgen has agreed to co-develop and co-commercialize with Kyowa Kirin its Phase III-bound KHK4083, a potentially first-in-class treatment for atopic dermatitis, through a collaboration that ...